HCP Live June 9, 2024
The global, real-world TRACE study was designed to improve the understanding of tralokinumab’s safety, efficacy, and clinical utilization in daily practice for eczema.
A recent global, real-world study suggests that tralokinumab is being prescribed for atopic dermatitis (AD) patients as a first-line biologic option for treatment within the US, with a heavy burden of disease among patients and substantial impacts on quality of life being observed.1
This study, titled ‘Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE study in the United States,’ was published in the British Journal of Dermatologists. It was led by investigators such as April W. Armstrong, MD, MPH, professor and chief of dermatology at University...
Today's Sponsors
Today's Sponsor